Tag: buccal drug delivery system market overview

  • Buccal Drug Delivery System Market Expected To Grow At 10.7% CAGR Through 2030: What Businesses Need To Know

    Buccal Drug Delivery System Market Expected To Grow At 10.7% CAGR Through 2030: What Businesses Need To Know

    Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

    Buccal Drug Delivery System Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?

    The market for buccal drug delivery systems has seen significant growth in recent years. This market is expected to increase from $3.89 billion in 2025 to $4.32 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 11.2%. The historical growth can be linked to factors such as a rising preference for alternative drug administration methods, an expansion in treatments for chronic pain and angina, progress in mucoadhesive formulations, a growing demand for medications with quicker onset, and the broadening of oral pharmaceutical manufacturing.

    The market for buccal drug delivery systems is anticipated to expand quickly over the coming years. Its valuation is projected to reach $6.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This expansion during the projection period stems from factors such as augmented investments in transmucosal drug investigations, a heightened need for smoking cessation treatments, the proliferation of personalized drug delivery systems, a stronger emphasis on formulations that promote compliance, and the accelerated creation of innovative buccal medications. Key trends anticipated during the forecast period encompass a wider acceptance of buccal and sublingual dosage methods, an escalating requirement for swift drug absorption mechanisms, a greater concentration on drug delivery systems that are convenient for patients, the evolution of controlled-release buccal formulations, and an intensified focus on non-invasive therapeutic options.

    Get A Free Sample Report With In-Depth Market Insights:

    https://thebusinessresearchcompany.com/sample_request?id=42839220&type=smp&name=Buccal%20Drug%20Delivery%20System%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

    Buccal Drug Delivery System Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

    The increasing occurrence of long-term illnesses is anticipated to fuel the expansion of the buccal drug delivery systems market in the future. Chronic conditions are defined as health problems lasting a year or more, including examples like cancer, heart disease, stroke, diabetes, and arthritis. These common chronic ailments, which require ongoing nutritional and medical support, are manageable but currently incurable. For many individuals living with chronic diseases like diabetes and cancer, buccal drug delivery systems offer suitable and efficient methods for administering mucosal and transmucosal medications. As an illustration, in June 2024, data from the National Health Service, a UK-based government body, indicated that in 2023, 3,615,330 people registered with a general practitioner (GP) were identified with non-diabetic hyperglycemia or pre-diabetes (a state of elevated blood sugar not yet meeting diabetes criteria). This represented an 18% rise from 3,065,825 instances recorded in 2022. Consequently, the growing incidence of chronic conditions is a key factor boosting the expansion of the buccal drug delivery systems market.

    Buccal Drug Delivery System Market Segments: Where Is Growth Concentrated?

    The buccal drug delivery system market covered in this report is segmented –

    1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays

    2) By Application: Pain Management, Smoking Cessation, Angina Pectoris

    3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

    Subsegments:

    1) By Sublingual: Sublingual Tablets, Sublingual Films

    2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges

    3) By Oral Sprays: Spray Solutions, Spray Gels

    Buccal Drug Delivery System Market Innovation Trends Shaping Future Development

    Leading companies active in the buccal drug delivery systems market are concentrating on launching products, such as melatonin oral spray, to increase their revenues. Melatonin oral spray is a form of melatonin supplementation provided in a spray format for oral application. For example, in February 2023, Arlak Biotech Private Limited, an India-based pharmaceutical company, introduced melatonin oral spray. This spray assists the body’s inherent melatonin production, consequently improving sleep quality in a straightforward and efficient manner. The medication offers a rapid remedy for individuals struggling with initiating sleep, maintaining sleep, or adjusting to various sleep patterns. Its swift and uncomplicated oral absorption facilitates a quicker initiation of sleep and enhanced sleep quality.

    Buccal Drug Delivery System Market Company Landscape And Competitive Strategy

    Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, Opiant Pharmaceuticals Inc

    View The Full Buccal Drug Delivery System Market Report:

    https://thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Sep_PR

    Buccal Drug Delivery System Market Largest Region: Which Geography Holds The Biggest Share?

    North America was the largest region in the buccal drug delivery systems market share in 2025. The regions covered in the buccal drug delivery system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Reach Out To Our Team:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Buccal Drug Delivery System Market Forecast Covering Industry Demand And Market Evolution

    Buccal Drug Delivery System Market Forecast Covering Industry Demand And Market Evolution

    The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

    What Market Size Is Forecasted For The Buccal Drug Delivery System Market By 2030 Based On Its 2026 Value?

    The buccal drug delivery system market has experienced swift expansion recently. It is projected to grow from $3.89 billion in 2025 to $4.32 billion in 2026, progressing at a compound annual growth rate (CAGR) of 11.2%. This historical growth is attributable to an increased preference for alternative drug delivery methods, the expansion of chronic pain and angina treatments, advancements in mucoadhesive formulations, a rising need for medications with a faster onset, and the broadening of oral pharmaceutical manufacturing.

    The buccal drug delivery system market is anticipated to experience substantial growth in the upcoming years, expanding to $6.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This projected increase is driven by heightened investments in transmucosal drug research, a rising demand for smoking cessation therapies, the expansion of personalized drug delivery systems, a growing focus on compliance-friendly formulations, and the increasing development of novel buccal drugs. Key trends expected in this forecast period include the increasing adoption of buccal and sublingual dosage forms, a rising demand for rapid drug absorption systems, an increased focus on patient-friendly drug delivery, the expansion of controlled-release buccal formulations, and an enhanced emphasis on non-invasive therapies.

    Download A Free Sample Report For Comprehensive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

    What Primary Factors Are Fueling The Expansion Of The Buccal Drug Delivery System Market?

    The increasing occurrence of chronic diseases is expected to propel the growth of the buccal drug delivery systems market going forward. These conditions persist for a year or longer, encompassing ailments such as cancer, heart disease, stroke, diabetes, and arthritis. Such common long-term illnesses are manageable rather than curable, necessitating continuous medical care and nutritional support. Buccal drug delivery systems offer suitable and efficient methods for administering mucosal and transmucosal drugs, which are essential for many patients with chronic conditions like diabetes and cancer. For instance, the National Health Service, a UK-based government department, reported in June 2024 that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023. This marked an 18% increase from 3,065,825 cases in 2022. Consequently, the expanding prevalence of chronic diseases is a key factor driving the buccal drug delivery systems market.

    What Are The Major Segment Categories Within The Buccal Drug Delivery System Market?

    The buccal drug delivery system market covered in this report is segmented –

    1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays

    2) By Application: Pain Management, Smoking Cessation, Angina Pectoris

    3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

    Subsegments:

    1) By Sublingual: Sublingual Tablets, Sublingual Films

    2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges

    3) By Oral Sprays: Spray Solutions, Spray Gels

    What Trends Are Influencing The Future Of The Buccal Drug Delivery System Market?

    Companies operating significantly within the buccal drug delivery systems market are concentrating on introducing new products, such as melatonin oral spray, to enhance their market revenues. Melatonin oral spray is a form of melatonin supplement presented in a spray format for oral application. For example, in February 2023, Arlak Biotech Private Limited, an India-based pharmaceutical company, introduced a melatonin oral spray. This spray supports the body’s inherent melatonin production, thus improving sleep quality in a straightforward and efficient manner. This remedy offers a rapid solution for individuals who struggle with initiating sleep, maintaining sleep, or adapting to various sleep schedules. The spray’s swift and easy oral absorption contributes to a quicker onset of sleep and superior sleep quality.

    Who Are The Leading Firms Participating In The Buccal Drug Delivery System Market?

    Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, Opiant Pharmaceuticals Inc

    Access The Complete Buccal Drug Delivery System Market Report:

    https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

    Which Regional Market Leads The Buccal Drug Delivery System Market?

    North America was the largest region in the buccal drug delivery systems market share in 2025. The regions covered in the buccal drug delivery system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Access a Customized Buccal Drug Delivery System Market Report for Deeper Competitive Insights

    https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp

    Browse Through More Reports Similar to the Global Buccal Drug Delivery System Market 2026, By The Business Research Company

    Gastroretentive Drug Delivery Systems Outsourcing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/gastroretentive-drug-delivery-systems-outsourcing-global-market-report

    Pharmaceutical Drug Delivery Market Report 2026

    https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

    Advanced Drug Delivery Systems Market Report 2026

    https://www.thebusinessresearchcompany.com/report/advanced-drug-delivery-systems-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas: +1 310-496-7795

    Asia: +44 7882 955267 & +91 8897263534

    Europe: +44 7882 955267

    Email us at: marketing@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Buccal Drug Delivery System Market Analysis 2026–2030 With Strategic Insights

    Global Buccal Drug Delivery System Market Analysis 2026–2030 With Strategic Insights

    The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

    What Changes In Market Value Are Expected For The Buccal Drug Delivery System Market Over The 2026–2030 Period?

    The market for buccal drug delivery systems has experienced rapid expansion recently. Projections indicate a rise from $3.89 billion in 2025 to $4.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.2%. This historical growth is primarily due to factors such as a growing preference for alternative drug delivery methods, an increase in treatments for chronic pain and angina, developments in mucoadhesive formulations, a heightened need for quicker-acting medications, and the expansion of oral pharmaceutical production.

    The market for buccal drug delivery systems is anticipated to experience substantial expansion in the coming years. This market is projected to reach $6.48 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.7%. Factors contributing to this growth during the forecast period include greater investments in transmucosal drug research, an uptick in the demand for smoking cessation therapies, the broadening of personalized drug delivery systems, an intensified focus on compliance-friendly formulations, and the increased development of new buccal drugs. Key trends anticipated during this period involve a wider embrace of buccal and sublingual dosage forms, a growing need for swift drug absorption systems, an enhanced emphasis on patient-centric drug delivery, the enlargement of controlled-release buccal formulations, and a heightened focus on non-invasive therapies.

    Access Your Free Sample Report For In-Depth Market Analysis:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

    Which Important Drivers Are Guiding The Buccal Drug Delivery System Market Growth?

    The growing occurrence of chronic illnesses is anticipated to fuel the expansion of the buccal drug delivery systems market in the future. Chronic diseases are defined as conditions that endure for at least a year, encompassing ailments such as cancer, heart disease, stroke, diabetes, and arthritis. These widespread chronic conditions, though manageable, are incurable and demand ongoing nutritional and medical attention. Buccal drug delivery systems offer suitable and efficient means for delivering mucosal and transmucosal medications, essential for numerous patients battling chronic ailments like diabetes and cancer. As an illustration, in June 2024, data from the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) had been diagnosed with non-diabetic hyperglycemia or pre-diabetes (a state characterized by elevated blood sugar levels, insufficient for a diabetes classification) in 2023. This represented an 18% rise from 3,065,825 cases recorded in 2022. Consequently, the increasing incidence of chronic diseases is a significant impetus for the expansion of the buccal drug delivery systems market.

    How Are Different Segments Classified In The Buccal Drug Delivery System Market Segment Analysis?

    The buccal drug delivery system market covered in this report is segmented –

    1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays

    2) By Application: Pain Management, Smoking Cessation, Angina Pectoris

    3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

    Subsegments:

    1) By Sublingual: Sublingual Tablets, Sublingual Films

    2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges

    3) By Oral Sprays: Spray Solutions, Spray Gels

    What Trends Are Influencing The Evolution Of The Buccal Drug Delivery System Market?

    Major companies in the buccal drug delivery systems market are concentrating on launching new products, such as melatonin oral spray, to increase their revenue. Melatonin oral spray is a form of melatonin supplementation designed for oral use in a spray format. For instance, in February 2023, Arlak Biotech Private Limited, an India-based pharmaceutical company, launched a melatonin oral spray. This spray supports the body’s natural production of melatonin, thereby enhancing sleep quality in an easy and effective manner. This medication offers a quick solution for those facing challenges with falling asleep, staying asleep, or adjusting to different sleep regimens. The spray’s rapid and easy oral absorption facilitates a quicker initiation of sleep and improved sleep quality.

    Who Are The Companies Driving Activity In The Buccal Drug Delivery System Market?

    Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, Opiant Pharmaceuticals Inc

    Get The Full Buccal Drug Delivery System Market Report:

    https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

    Which Region Holds The Highest Market Share In The Buccal Drug Delivery System Market?

    North America was the largest region in the buccal drug delivery systems market share in 2025. The regions covered in the buccal drug delivery system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Buccal Drug Delivery System Market Report For Competitive Insights:

    https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp

    Browse Through More Reports Similar to the Global Buccal Drug Delivery System Market 2026, By The Business Research Company

    Gastroretentive Drug Delivery Systems Outsourcing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/gastroretentive-drug-delivery-systems-outsourcing-global-market-report

    Pharmaceutical Drug Delivery Market Report 2026

    https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

    Advanced Drug Delivery Systems Market Report 2026

    https://www.thebusinessresearchcompany.com/report/advanced-drug-delivery-systems-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Buccal Drug Delivery System Market Analysis 2026–2030 Offering Strategic Forecast Insights for Businesses

    Global Buccal Drug Delivery System Market Analysis 2026–2030 Offering Strategic Forecast Insights for Businesses

    The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

    What Is The Forecasted Market Value Of The Buccal Drug Delivery System Market Across 2026–2030?

    The buccal drug delivery system market size has seen swift expansion in recent times. It is anticipated to increase from $3.89 billion in 2025 to $4.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.2%. Several factors contributed to its growth historically, including a rising preference for alternative drug administration methods, an increase in treatments for chronic pain and angina, breakthroughs in mucoadhesive formulations, a greater demand for medications with faster onset, and the broadening of oral pharmaceutical manufacturing.

    The buccal drug delivery system market is projected to experience substantial growth over the coming years. This market is forecast to reach $6.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This expansion during the forecast period is driven by factors such as increased investments in transmucosal drug research, a rising need for smoking cessation treatments, the expansion of personalized drug delivery systems, a greater emphasis on formulations that enhance compliance, and the growing development of new buccal drugs. Key trends anticipated within this period involve the increasing embrace of buccal and sublingual dosage forms, a heightened demand for systems that enable rapid drug absorption, an escalating focus on patient-friendly methods for drug delivery, the broadening of controlled-release buccal formulations, and an increased emphasis on non-invasive therapeutic approaches.

    Download the Free Sample Report to Explore Key Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

    What Major Growth Drivers Are Shaping The Outlook Of The Buccal Drug Delivery System Market?

    The increasing occurrence of chronic illnesses is anticipated to drive the expansion of the buccal drug delivery systems market. Chronic diseases refer to conditions that persist for a year or longer, encompassing ailments such as cancer, heart disease, stroke, diabetes, cancer, and arthritis. These are widely prevalent chronic illnesses that, while manageable and not curable, necessitate continuous nutritional and medical attention. Buccal drug delivery systems provide appropriate and effective drug delivery for administering mucosal and transmucosal drugs required by numerous patients suffering from chronic diseases, including diabetes and cancer. For instance, in June 2024, the National Health Service, a UK-based government department, indicated that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, an 18% increase from 3,065,825 cases in 2022. Thus, the growing prevalence of chronic diseases is propelling the growth of the buccal drug delivery systems market.

    What Segmentation Levels Are Considered In The Buccal Drug Delivery System Market?

    The buccal drug delivery system market covered in this report is segmented –

    1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays

    2) By Application: Pain Management, Smoking Cessation, Angina Pectoris

    3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

    Subsegments:

    1) By Sublingual: Sublingual Tablets, Sublingual Films

    2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges

    3) By Oral Sprays: Spray Solutions, Spray Gels

    What Trends Are Projected To Affect The Buccal Drug Delivery System Market?

    Major companies in the buccal drug delivery systems market are concentrating on launching products, such as melatonin oral spray, to increase their revenues. Melatonin oral spray is a form of melatonin supplementation designed as a spray for oral application. For instance, in February 2023, Arlak Biotech Private Limited, an India-based pharmaceutical company, introduced a melatonin oral spray. This spray aids the body’s natural melatonin production, thereby improving sleep quality in an easy and effective manner. The medication offers a rapid solution for individuals who struggle with falling asleep, staying asleep, or adjusting to various sleep patterns. The spray’s fast and simple oral absorption contributes to a quicker onset of sleep and enhanced sleep quality.

    Which Leading Firms Are Contributing To The Growth Of The Buccal Drug Delivery System Market?

    Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, Opiant Pharmaceuticals Inc

    Read the full buccal drug delivery system market report here:

    https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

    Which Regions Are Projected To Dominate The Buccal Drug Delivery System Market In The Coming Years?

    North America was the largest region in the buccal drug delivery systems market share in 2025. The regions covered in the buccal drug delivery system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Tailored Buccal Drug Delivery System Market Research Report For Competitive Advantage:

    https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp

    Browse Through More Reports Similar to the Global Buccal Drug Delivery System Market 2026, By The Business Research Company

    Gastroretentive Drug Delivery Systems Outsourcing Market Report 2026

    https://www.thebusinessresearchcompany.com/report/gastroretentive-drug-delivery-systems-outsourcing-global-market-report

    Pharmaceutical Drug Delivery Market Report 2026

    https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

    Advanced Drug Delivery Systems Market Report 2026

    https://www.thebusinessresearchcompany.com/report/advanced-drug-delivery-systems-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Buccal Drug Delivery System Market Report 2026: Strategic Insights and Revenue Outlook

    Buccal Drug Delivery System Market Report 2026: Strategic Insights and Revenue Outlook

    Uncover key drivers, emerging technologies, and competitive movements shaping the semiconductor timing integrated circuit (ic) market from 2026–2035 with trusted insights from The Business Research Company

    How is the Buccal Drug Delivery System Market size predicted to change over the forecast window of 2026–2035?_x000D_

    The buccal drug delivery system market has experienced substantial expansion in recent years. This market is projected to expand from $3.89 billion in 2025 to $4.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.2%. Historically, this growth stemmed from a heightened preference for alternative drug delivery methods, an increase in treatments for chronic pain and angina, developments in mucoadhesive formulations, a greater need for medications with quicker onset, and the expansion of oral pharmaceutical production._x000D_

    _x000D_

    The buccal drug delivery system market is expected to experience significant growth in the coming years, with forecasts showing it will reach $6.48 billion by 2030, at a compound annual growth rate (CAGR) of 10.7%. This expansion is attributed to various factors including increased investments in transmucosal drug research, a rising demand for smoking cessation therapies, the broader adoption of personalized drug delivery systems, an intensified focus on compliance-friendly formulations, and the accelerated development of novel buccal drugs. Throughout the forecast period, key trends are set to include the wider acceptance of buccal and sublingual dosage forms, a growing need for rapid drug absorption systems, a greater emphasis on patient-friendly drug delivery, the enlargement of controlled-release buccal formulations, and an enhanced focus on non-invasive therapies._x000D_

    _x000D_

    #Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp_x000D_

    _x000D_

    Which Drivers Are Contributing To The Expansion Of The Buccal Drug Delivery System Market?_x000D_

    The rising incidence of chronic diseases is anticipated to fuel the expansion of the buccal drug delivery systems market moving forward. Chronic diseases are defined as ailments that persist for a minimum of a year, encompassing conditions such as cancer, heart disease, stroke, diabetes, and arthritis. These prevalent, incurable illnesses necessitate continuous medical care and nutritional support for management. For numerous patients battling chronic conditions like diabetes and cancer, buccal drug delivery systems provide an appropriate and efficient means for administering required mucosal and transmucosal drugs. For example, data from June 2024 released by the National Health Service, a UK-based government department, revealed that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a condition characterized by elevated blood sugar levels, insufficient for a diabetes diagnosis) in 2023. This marked an 18% surge from 3,065,825 cases recorded in 2022. Consequently, the increasing prevalence of chronic diseases drives the growth of the buccal drug delivery systems market._x000D_

    _x000D_

    What Segment Classifications Make Up The Buccal Drug Delivery System Market?_x000D_

    The buccal drug delivery system market covered in this report is segmented – _x000D_

    _x000D_

    1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays_x000D_

    2) By Application: Pain Management, Smoking Cessation, Angina Pectoris_x000D_

    3) By End-User: Hospitals, Ambulatory Centers, Other End-Users_x000D_

    _x000D_

    Subsegments:_x000D_

    1) By Sublingual: Sublingual Tablets, Sublingual Films_x000D_

    2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges_x000D_

    3) By Oral Sprays: Spray Solutions, Spray Gels_x000D_

    _x000D_

    Which Market Trends Are Opening Growth Opportunities In The Buccal Drug Delivery System Market?_x000D_

    Leading companies active in the buccal drug delivery systems market are emphasizing new product introductions, such as melatonin oral spray, to boost their market revenues. Melatonin oral spray is a type of melatonin supplement designed for oral administration in a spray form. For example, in February 2023, Arlak Biotech Private Limited, an India-based pharmaceutical firm, unveiled its melatonin oral spray. This spray assists the body’s natural melatonin production, thus enhancing sleep quality through a convenient and effective method. The medication offers a rapid remedy for individuals struggling to fall asleep, stay asleep, or adjust to various sleep patterns. Its quick and simple oral absorption facilitates a faster onset of sleep and improved sleep quality._x000D_

    _x000D_

    Which Key Players Are Driving Competition In The Buccal Drug Delivery System Market?_x000D_

    Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd, Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc, Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd, AstraZeneca PLC, Dr. Reddy’s Laboratories Ltd, Takeda Pharmaceutical Company Limited, Novartis AG, Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc, NAPP Pharmaceutical Ltd, Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc, Par Pharmaceutical Companies Inc, Acorda Therapeutics Inc, Opiant Pharmaceuticals Inc _x000D_

    _x000D_

    #Access The Complete Report For Deeper Market Insights:#_x000D_

    https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report_x000D_

    _x000D_

    Which Region Is Projected To Lead The Buccal Drug Delivery System Market During The Forecast Period?_x000D_

    North America was the largest region in the buccal drug delivery systems market share in 2025. The regions covered in the buccal drug delivery system market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

    _x000D_

    #Request Your Customized Buccal Drug Delivery System Market Research Report for Competitive Advantage:#_x000D_

    https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp_x000D_

    _x000D_

    #Browse Through More Reports Similar to the Global Buccal Drug Delivery System Market 2026, By The Business Research Company#_x000D_

    _x000D_

    Gastroretentive Drug Delivery Systems Outsourcing Global Market Report 2026_x000D_

    https://www.thebusinessresearchcompany.com/report/gastroretentive-drug-delivery-systems-outsourcing-global-market-report_x000D_

    _x000D_

    Pharmaceutical Drug Delivery Global Market Report 2026_x000D_

    https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report_x000D_

    _x000D_

    Advanced Drug Delivery Systems Global Market Report 2026_x000D_

    https://www.thebusinessresearchcompany.com/report/advanced-drug-delivery-systems-global-market-report_x000D_

    _x000D_

    #Get in touch with us:#_x000D_

    _x000D_

    The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

    Americas +1 310-496-7795_x000D_

    Asia +44 7882 955267 & +91 8897263534_x000D_

    Europe +44 7882 955267_x000D_

    Email us at info@tbrc.info_x000D_

    _x000D_

    #Follow us on:#_x000D_

    _x000D_

    LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

  • Buccal Drug Delivery System Market Expansion to $5.88 Billion by 2029: Key Drivers and Trends

    Buccal Drug Delivery System Market Expansion to $5.88 Billion by 2029: Key Drivers and Trends

    Uncover key drivers, emerging technologies, and competitive movements shaping the buccal drug delivery system market from 2025–2034 with trusted insights from The Business Research Company

    What Is The Base Market Size For The Buccal Drug Delivery System Market Today And What Will It Reach By 2029?

    The buccal drug delivery system market has shown robust expansion in recent years. Its size is expected to climb from $3.55 billion in 2024 to $3.89 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.5%. The notable growth observed in prior periods stems from early innovations in drug delivery, widespread adoption by the pharmaceutical industry, successful clinical studies demonstrating efficacy, effective market penetration strategies, and the development of applications for specific diseases.

    The buccal drug delivery system market size is poised for substantial expansion over the next few years. It is forecast to increase to $5.88 billion by 2029, achieving a compound annual growth rate (CAGR) of 10.9%. This projected growth can be ascribed to several factors, including patient-centric drug delivery methods, an expanding geriatric demographic, the increasing need for targeted therapies, the delivery of biologics and peptides, supportive regulatory environments and approvals, and heightened investments in research and development. Significant developments anticipated during this period involve enhanced patient convenience and compliance, innovations in drug formulations, the rising incidence of chronic diseases, specialized care for pediatric and geriatric populations, and improved bioavailability of drugs.

    Access A Free Sample Of The Report:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

    What Factors Are Boosting The Buccal Drug Delivery System Market?

    The increasing occurrence of chronic diseases is anticipated to propel the future expansion of the buccal drug delivery systems market. Chronic diseases are ailments that persist for a year or longer, encompassing conditions such as cancer, heart disease, stroke, diabetes, cancer, and arthritis. These are prevalent chronic illnesses that, while manageable, cannot be cured and thus necessitate continuous nutritional and medical attention. Buccal drug delivery systems offer an appropriate and effective method for administering mucosal and transmucosal drugs, which are essential for many patients suffering from chronic diseases like diabetes and cancer. For instance, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths globally, representing 74% of the total, were annually caused by non-communicable diseases (NCDs) or chronic diseases. Specifically, cardiovascular diseases were responsible for 17.9 million deaths, cancer for 9.3 million deaths, chronic respiratory diseases for 4.1 million deaths, and diabetes for 2.0 million deaths. Therefore, the rising prevalence of chronic diseases is a driving force behind the growth of the buccal drug delivery systems market.

    How Is The Buccal Drug Delivery System Market Categorized By Application, Type, And Region?

    The buccal drug delivery systemmarket covered in this report is segmented –

    1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays

    2) By Application: Pain Management, Smoking Cessation, Angina Pectoris

    3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

    Subsegments:

    1) By Sublingual: Sublingual Tablets, Sublingual Films

    2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges

    3) By Oral Sprays: Spray Solutions, Spray Gels

    How Are Technological Trends Affecting The Buccal Drug Delivery System Market Growth?

    Leading companies in the buccal drug delivery systems market are focusing on developing innovative solutions, such as oral treatments for plaque psoriasis, to improve patient outcomes and enhance the efficacy of drug delivery. Oral treatment for plaque psoriasis refers to the administration of medications taken by mouth to manage and alleviate the symptoms of this chronic autoimmune condition, characterized by the rapid growth of skin cells leading to thick, red, scaly patches. For instance, in September 2022, Bristol Myers Squibb, a US-based pharmaceutical company, received FDA approval for Sotyktu (deucravacitinib), an oral treatment for adults with moderate-to-severe plaque psoriasis. This approval marks the first new oral therapy for this condition in nearly a decade, offering a novel mechanism of action as a selective inhibitor of tyrosine kinase 2 (TYK2).

    Who Are The Global Leaders Steering The Buccal Drug Delivery System Market Forward?

    Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd., Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc., Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd., AstraZeneca PLC, F Hoffmann-La Roche Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Novo Nordisk A/S, Ethypharm SAS, Applied Pharma Research SA, Sunovion Pharmaceuticals Inc., Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc., NAPP Pharmaceutical Ltd., Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc., Par Pharmaceutical Companies Inc., Acorda Therapeutics Inc., Opiant Pharmaceuticals Inc.

    Download The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

    Which Region Is Projected To Achieve The Fastest Growth In The Buccal Drug Delivery System Market?

    North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Get A Report Customized For You Here:

    https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp

    Browse Through More Reports Similar to the Global Buccal Drug Delivery System Market 2025, By The Business Research Company

    Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Implantable Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/implantable-drug-delivery-devices-global-market-report

    Injectable Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/injectable-drug-delivery-devices-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Buccal Drug Delivery System Market Projected to Expand at 10.9% CAGR by 2029

    Global Buccal Drug Delivery System Market Projected to Expand at 10.9% CAGR by 2029

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    How Much Was The Buccal Drug Delivery System Market Worth In 2025, And What Is Its Anticipated Value By 2029?

    The market encompassing buccal drug delivery systems has experienced robust expansion recently, projected to escalate from a valuation of $3.55 billion in the year 2024 to $3.89 billion by 2025, reflecting a compound annual growth rate of 9.5%. This upswing observed during the historical span is underpinned by factors such as the emergence of pioneering drug delivery technologies, increasing acceptance within the pharmaceutical sector, demonstrated clinical success and effectiveness, the implementation of targeted market entry approaches, and specialized uses tailored to particular ailments.

    The projected trajectory for the buccal drug delivery system market indicates substantial expansion in the coming years, with its valuation anticipated to reach $5.88 billion by 2029, fueled by a compound annual growth rate (CAGR) of 10.9%; this surge during the projection timeframe stems from factors such as an increasing focus on patient-centered administration methods, the growing proportion of elderly individuals, the escalating need for precision therapies, the delivery of biologics and peptides, supportive regulatory frameworks and clearances, alongside considerable investment in research and development initiatives, while prominent developments anticipated to shape this era encompass heightened emphasis on patient ease of use and adherence, ongoing innovations in medicinal preparations, the increasing prevalence of long-term health conditions, specialized attention to pediatric and elderly populations, and improved absorption rates of active ingredients.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

    What Are The Top Growth Drivers Impacting The Buccal Drug Delivery System Market Outlook?

    The increasing incidence of long-term health conditions is projected to fuel the expansion within the buccal drug delivery systems market in the near future. Chronic ailments, defined as conditions spanning a year or more, encompass numerous persistent health issues like diabetes, heart conditions, stroke, and various forms of cancer, alongside arthritis; these widespread illnesses demand ongoing medical attention and nutritional management as they are typically manageable rather than curable. Buccal delivery mechanisms offer a suitable and efficacious route for administering medications intended for mucosal and transmucosal absorption, a necessity for numerous individuals afflicted with chronic diseases such as cancer and diabetes. To illustrate the scale, the World Health Organization, a United Nations agency based in Switzerland, reported in September 2023 that chronic diseases, or non-communicable diseases (NCDs), were responsible for 41 million fatalities annually worldwide, accounting for three-quarters of all deaths; specifically, cardiovascular ailments caused 17.9 million deaths, cancers resulted in 9.3 million deaths, chronic respiratory conditions led to 4.1 million deaths, and diabetes was the cause of 2.0 million deaths. Consequently, the escalating rate of chronic disease occurrence serves as a significant catalyst for the growth trajectory of the buccal drug delivery systems market.

    What Are The Major Segment Types Covered In The Buccal Drug Delivery System Market?

    The buccal drug delivery systemmarket covered in this report is segmented –

    1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays

    2) By Application: Pain Management, Smoking Cessation, Angina Pectoris

    3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

    Subsegments:

    1) By Sublingual: Sublingual Tablets, Sublingual Films

    2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges

    3) By Oral Sprays: Spray Solutions, Spray Gels

    Which Market Trends Are Creating New Opportunities In The Buccal Drug Delivery System Industry?

    Leading enterprises within the buccal drug delivery systems sector are concentrating their efforts on engineering novel therapeutic avenues, notably oral modalities for managing plaque psoriasis, with the goal of elevating patient health results and boosting the performance of drug administration. The concept of an oral treatment for plaque psoriasis involves medicaments ingested orally designed to control and reduce the manifestations of this persistent autoimmune disorder, which involves accelerated skin cell proliferation resulting in the formation of dense, crimson, scaly areas. To illustrate this progress, the US pharmaceutical giant, Bristol Myers Squibb, secured authorization from the FDA in September 2022 for Sotyktu (deucravacitinib), an ingestible medication intended for adults afflicted with plaque psoriasis of moderate to severe intensity. This governmental clearance signifies the introduction of the first innovative systemic drug for this ailment in roughly ten years, presenting a distinct therapeutic pathway as a selective inhibitor targeting tyrosine kinase 2 (TYK2).

    Which Leading Companies Dominate The Buccal Drug Delivery System Market Share?

    Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd., Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc., Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd., AstraZeneca PLC, F Hoffmann-La Roche Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Novo Nordisk A/S, Ethypharm SAS, Applied Pharma Research SA, Sunovion Pharmaceuticals Inc., Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc., NAPP Pharmaceutical Ltd., Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc., Par Pharmaceutical Companies Inc., Acorda Therapeutics Inc., Opiant Pharmaceuticals Inc.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

    Which Regional Markets Are Contributing Most To The Buccal Drug Delivery System Industry Expansion?

    North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Buccal Drug Delivery System Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp

    Browse Through More Reports Similar to the Global Buccal Drug Delivery System Market 2025, By The Business Research Company

    Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report

    Implantable Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/implantable-drug-delivery-devices-global-market-report

    Injectable Drug Delivery Devices Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/injectable-drug-delivery-devices-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Buccal Drug Delivery System Market Projected to Reach $5.88 Billion by 2029 at a CAGR of 10.9%

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What is the Projected CAGR for the Buccal Drug Delivery System Market Size from 2025 to 2034?

    The market size of the buccal drug delivery system has significantly expanded in the past few years. It is projected to increase from $3.55 billion in 2024 to $3.89 billion in 2025, showcasing a compound annual growth rate (CAGR) of 9.5%. This substantial growth in the previous period is attributed to drug delivery innovation at an early stage, adoption by the pharmaceutical industry, effectiveness demonstrated through clinical studies, strategic market penetration, and applications specific to certain diseases.

    The buccal drug delivery system market is predicted to experience a significant boost in its size in the upcoming years. The market is projected to reach a value of $5.88 billion by 2029, expanding at a compound annual growth rate (CAGR) of 10.9%. Factors contributing to the growth during the forecast period include patient-oriented drug delivery, an increasing ageing population, the need for targeted treatments, and delivery of biologics and peptides, as well as regulatory support and approvals, and investments in research and development. Noteworthy trends for the forecast period encompass patient comfort and adherence, progression in drug formulations, the surge in chronic illnesses, care for pediatric and geriatric patients, and improved bioavailability.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

    What Are the Major Market Drivers Behind the Rising Adoption of Buccal Drug Delivery System Market?

    The growth of the buccal drug delivery systems market is anticipated to be driven by the increasing incidence of chronic diseases. Chronic diseases, such as diabetes, cancer, heart disease, stroke, and arthritis, are conditions that last for over a year and, while they can be managed, they cannot be cured. These diseases require ongoing medical care and nutrition. The administration of mucosal and transmucosal drugs, necessary for many patients with chronic diseases like cancer and diabetes, is effectively and appropriately supported by buccal drug delivery systems. The World Health Organization, a specialized agency of the United Nations based in Switzerland, reported in September 2023 that of the 41 million deaths caused by non-communicable diseases (NCDs) or chronic diseases globally each year, 74% were due to chronic diseases. This included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Consequently, the buccal drug delivery systems market’s growth is being fueled by the increasing incidence of chronic diseases.

    Which Key Market Segments Comprise the Buccal Drug Delivery System Market and Drive Its Revenue Growth?

    The buccal drug delivery systemmarket covered in this report is segmented –

    1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays

    2) By Application: Pain Management, Smoking Cessation, Angina Pectoris

    3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

    Subsegments:

    1) By Sublingual: Sublingual Tablets, Sublingual Films

    2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges

    3) By Oral Sprays: Spray Solutions, Spray Gels

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp

    Which Areas Are Leading Regions in the Buccal Drug Delivery System Market Expansion Across the Globe?

    North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Strategic Trends Steering theBuccal Drug Delivery System Market Direction?

    Leading firms in the buccal drug delivery systems market are concentrating on the development of innovative solutions, including oral therapies for plaque psoriasis. This approach is aimed at maximizing patient benefits and augmenting the efficiency of drug delivery. Oral therapies for plaque psoriasis entail the oral administration of drugs to control and ease the signs of plaque psoriasis. This is a chronic autoimmune disorder typified by rapid skin cell proliferation leading to the formation of thick, crimson patches coated with scales. For example, Bristol Myers Squibb, a pharmaceutical firm based in the US, received FDA authorization for Sotyktu (deucravacitinib) in September 2022. This oral therapy is designed for adults suffering from moderate-to-severe plaque psoriasis. The FDA’s approval signals the inception of the first new oral treatment for this condition in nearly ten years. Its unique mechanism of action centers on selectively inhibiting tyrosine kinase 2 (TYK2).

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

    How Is the Buccal Drug Delivery System Market Conceptually Defined?

    The buccal drug delivery system refers to the injection of the desired medicine through the buccal mucosal membrane lining of the mouth cavity. This method is effective for administering mucosal and transmucosal drugs. Mucosal drug delivery aims for site-specific drug release on the mucosa, whereas transmucosal permeation entails drug absorption across the mucosal barrier and into the systemic circulation.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8290

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Buccal Drug Delivery System Market Outlook 2025 – Insights for Executive and Strategic Planning

    Buccal Drug Delivery System Market Outlook 2025 – Insights for Executive and Strategic Planning

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Buccal Drug Delivery System Market Grown from 2024 to 2025?

    Recently, the scale of the buccal drug delivery system market has witnessed an accelerated expansion. The market size is projected to surge from $3.55 billion in 2024 to $3.91 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. This notable increase throughout the past years is credited to pioneering advancements in drug delivery, integration within the pharmaceutical sector, results from clinical trials and efficacy, strategic market penetration, and applications tailored to specific diseases.

    What Growth Rate Is Anticipated for the Buccal Drug Delivery System Market in the Coming Years?

    The market for buccal drug delivery systems is anticipated to expand significantly over the next several years, reaching a valuation of $5.97 billion in 2029, with a compound annual growth rate (CAGR) of 11.1%. This growth during the forecast period is due to factors like the emphasis on patient-focused drug administration, the increase in elderly population, the need for targeted treatments, biologics and peptides delivery, as well as regulatory backing and approvals, and investment in research and development. A few trends projected for this period are a focus on patient comfort and adherence, improvements in drug formulations, the rise of chronic illnesses, care for elderly and children, and improved drug bioavailability.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

    Who Are the Leading Companies in the Buccal Drug Delivery System Market?

    Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd., Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc., Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd., AstraZeneca PLC, F Hoffmann-La Roche Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Novo Nordisk A/S, Ethypharm SAS, Applied Pharma Research SA, Sunovion Pharmaceuticals Inc., Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc., NAPP Pharmaceutical Ltd., Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc., Par Pharmaceutical Companies Inc., Acorda Therapeutics Inc., Opiant Pharmaceuticals Inc.

    What Are the Key Drivers of the Buccal Drug Delivery System Market?

    Anticipations for the buccal drug delivery systems market’s growth are being fueled by the increasing prevalence of chronic diseases. Chronic diseases, typified by illnesses such as diabetes, cancer, arthritis, heart disease, and stroke, are persistent conditions that can last for a year or more. They require constant medical care and nutritional support as they can be managed but not cured. Buccal drug delivery systems offer an efficient route for delivering mucosal and transmucosal medications, which are needed by many patients dealing with chronic diseases such as cancer and diabetes. Based on data from the World Health Organization, a Switzerland-based UN subsidiary agency, in September 2023, chronic, or non-communicable diseases (NCDs) accounted for 74% of global deaths or 41 million fatalities. Breakdowns included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Hence, the escalating prevalence of chronic diseases is stimulating the growth of the buccal drug delivery systems market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp

    What Are the Key Market Segments in the Buccal Drug Delivery System Industry?

    The buccal drug delivery system market covered in this report is segmented –

    1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays

    2) By Application: Pain Management, Smoking Cessation, Angina Pectoris

    3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

    Subsegments:

    1) By Sublingual: Sublingual Tablets, Sublingual Films

    2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges

    3) By Oral Sprays: Spray Solutions, Spray Gels

    What Are the Latest Trends in the Buccal Drug Delivery System Market?

    Key players in the buccal drug delivery systems market are striving to introduce innovative solutions like oral treatment options for plaque psoriasis, with the aim of enhancing patient outcomes and advancing the effectiveness of drug delivery systems. Plaque psoriasis, a chronic autoimmune disease, is marked by rapid skin cell growth, resulting in thick, red, and scaly patches. These oral treatments are designed to manage and alleviate the symptoms of this condition. For instance, in September 2022, the U.S. pharmaceutical giant, Bristol Myers Squibb, obtained FDA approval for Sotyktu (deucravacitinib), a new oral remedy for adults suffering from moderate-to-severe plaque psoriasis. This was a significant milestone given that it was the first novel oral therapy for the condition to be approved in nearly ten years. It provides a new mechanism of action as a selective inhibitor of tyrosine kinase 2 (TYK2).

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

    What Are the Key Regional Markets in the Buccal Drug Delivery System Industry?

    North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8290

    This Report Delivers Insight On:

    1. How big is the buccal drug delivery system market, and how is it changing globally?

    2. Who are the major companies in the buccal drug delivery system market, and how are they performing?

    3. What are the key opportunities and risks in the buccal drug delivery system market right now?

    4. Which products or customer segments are growing the most in the buccal drug delivery system market?

    5. What factors are helping or slowing down the growth of the buccal drug delivery system market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 2071930708

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Buccal Drug Delivery System Market Outlook 2025 – Insights for Executive and Strategic Planning

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Buccal Drug Delivery System Market Grown from 2024 to 2025?

    Recently, the scale of the buccal drug delivery system market has witnessed an accelerated expansion. The market size is projected to surge from $3.55 billion in 2024 to $3.91 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. This notable increase throughout the past years is credited to pioneering advancements in drug delivery, integration within the pharmaceutical sector, results from clinical trials and efficacy, strategic market penetration, and applications tailored to specific diseases.

    What Growth Rate Is Anticipated for the Buccal Drug Delivery System Market in the Coming Years?

    The market for buccal drug delivery systems is anticipated to expand significantly over the next several years, reaching a valuation of $5.97 billion in 2029, with a compound annual growth rate (CAGR) of 11.1%. This growth during the forecast period is due to factors like the emphasis on patient-focused drug administration, the increase in elderly population, the need for targeted treatments, biologics and peptides delivery, as well as regulatory backing and approvals, and investment in research and development. A few trends projected for this period are a focus on patient comfort and adherence, improvements in drug formulations, the rise of chronic illnesses, care for elderly and children, and improved drug bioavailability.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp

    Who Are the Leading Companies in the Buccal Drug Delivery System Market?

    Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd., Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc., Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd., AstraZeneca PLC, F Hoffmann-La Roche Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Novo Nordisk A/S, Ethypharm SAS, Applied Pharma Research SA, Sunovion Pharmaceuticals Inc., Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc., NAPP Pharmaceutical Ltd., Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc., Par Pharmaceutical Companies Inc., Acorda Therapeutics Inc., Opiant Pharmaceuticals Inc.

    What Are the Key Drivers of the Buccal Drug Delivery System Market?

    Anticipations for the buccal drug delivery systems market’s growth are being fueled by the increasing prevalence of chronic diseases. Chronic diseases, typified by illnesses such as diabetes, cancer, arthritis, heart disease, and stroke, are persistent conditions that can last for a year or more. They require constant medical care and nutritional support as they can be managed but not cured. Buccal drug delivery systems offer an efficient route for delivering mucosal and transmucosal medications, which are needed by many patients dealing with chronic diseases such as cancer and diabetes. Based on data from the World Health Organization, a Switzerland-based UN subsidiary agency, in September 2023, chronic, or non-communicable diseases (NCDs) accounted for 74% of global deaths or 41 million fatalities. Breakdowns included 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Hence, the escalating prevalence of chronic diseases is stimulating the growth of the buccal drug delivery systems market.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp

    What Are the Key Market Segments in the Buccal Drug Delivery System Industry?

    The buccal drug delivery system market covered in this report is segmented –

    1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays

    2) By Application: Pain Management, Smoking Cessation, Angina Pectoris

    3) By End-User: Hospitals, Ambulatory Centers, Other End-Users

    Subsegments:

    1) By Sublingual: Sublingual Tablets, Sublingual Films

    2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges

    3) By Oral Sprays: Spray Solutions, Spray Gels

    What Are the Latest Trends in the Buccal Drug Delivery System Market?

    Key players in the buccal drug delivery systems market are striving to introduce innovative solutions like oral treatment options for plaque psoriasis, with the aim of enhancing patient outcomes and advancing the effectiveness of drug delivery systems. Plaque psoriasis, a chronic autoimmune disease, is marked by rapid skin cell growth, resulting in thick, red, and scaly patches. These oral treatments are designed to manage and alleviate the symptoms of this condition. For instance, in September 2022, the U.S. pharmaceutical giant, Bristol Myers Squibb, obtained FDA approval for Sotyktu (deucravacitinib), a new oral remedy for adults suffering from moderate-to-severe plaque psoriasis. This was a significant milestone given that it was the first novel oral therapy for the condition to be approved in nearly ten years. It provides a new mechanism of action as a selective inhibitor of tyrosine kinase 2 (TYK2).

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report

    What Are the Key Regional Markets in the Buccal Drug Delivery System Industry?

    North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8290

    This Report Delivers Insight On:

    1. How big is the buccal drug delivery system market, and how is it changing globally?

    2. Who are the major companies in the buccal drug delivery system market, and how are they performing?

    3. What are the key opportunities and risks in the buccal drug delivery system market right now?

    4. Which products or customer segments are growing the most in the buccal drug delivery system market?

    5. What factors are helping or slowing down the growth of the buccal drug delivery system market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model